Cosmos Week
A blood-pressure drug may activate health-promoting brown fat
BiologiaEdição em portuguêsFonte institucionalAtualização institucional

A blood-pressure drug may activate health-promoting brown fat

In a National Institutes of Health-funded study, scientists have demonstrated that the drug losartan, commonly prescribed for high blood pressure, boosts brown adipose tissue.

Fonte original citada e enquadrada editorialmente pelo Cosmos Week. NIH News Releases
Assinatura editorialRedação do Cosmos Week
Publicado20 nov 2026 22h18
Atualizado2026-11-20
Tipo de coberturaFonte institucional
Nível de evidênciaAtualização institucional
Leitura4 min de leitura

Pontos-chave

  • Em foco: In a National Institutes of Health-funded study, scientists have demonstrated that the drug losartan, commonly prescribed for high blood pressure
  • Detalhe: distinguir anúncio de evidência
  • Leitura editorial: release institucional, útil como fonte primária, mas não como validação independente.
Texto completo

In a National Institutes of Health-funded study, scientists have demonstrated that the drug losartan, commonly prescribed for high blood pressure, boosts brown adipose tissue activity in mice, enhancing their metabolism. In a National Institutes of Health (NIH)-funded study, scientists have demonstrated that the drug losartan, commonly prescribed for high blood pressure, boosts brown adipose tissue activity in mice, enhancing their metabolism.

Researchers initially discovered the connection between brown fat and the drug class to which losartan belongs, known as angiotensin receptor blockers (ARBs), through an analysis of over 100, 000 patients. This indicates that repurposing a widely used drug, with a well-known safety profile, may be a clinically viable method of stimulating brown fat, which has been linked to improved cardiovascular health and, identified for the first time in this study, psychiatric health.

D, director of NIH’s National Institute of Diabetes and Digestive and Kidney Disease (NIDDK). D, at Rockefeller University recently drew connections between brown fat and reduced prevalence of cardiovascular and metabolic disease.

D, and Daniel Lafontaine, used artificial intelligence techniques to identify brown fat associations among more than 100, 000 patients who received PET/CT imaging for cancer. They uncovered some new connections as well, including a lower incidence of anxiety and depression in patients with greater brown fat presence.

D, an instructor of clinical investigation at Rockefeller and an endocrinologist at Weill Cornell Medicine. NIH supported this research through NIDDK grant DP1DK139983, National Cancer Institute (NCI) grant P30CA008748, National Institute of General Medical Sciences (NIGMS) grant T32GM152349, and National Center for Advancing Translational Sciences (NCATS) grant UL1TR001866.

About the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): The NIDDK, a component of the National Institutes of Health (NIH), conducts and supports research on diabetes and other endocrine and metabolic diseases.

Fonte